The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Magenta Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Regeneron; Sanofi; Takeda
Speakers' Bureau - Clinical Care Options; Peerview
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - Caelum Biosciences
Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).
 
Darrell White
Honoraria - Amgen; Antengene; Bristol-Myers Squibb/Celgene; Forus; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; AVM Biotechnology; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Sumit Madan
Consulting or Advisory Role - Karyopharm Therapeutics; Sanofi
Speakers' Bureau - Janssen
 
Suzanne Lentzsch
No Relationships to Disclose
 
Evgeni Chubar
No Relationships to Disclose
 
Noa Lavi
No Relationships to Disclose
 
Dane R. Van Domelen
Employment - Karyopharm Therapeutics
 
Ohad S. Bentur
Employment - Karyopharm Therapeutics
 
Muhamed Baljevic
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Cardinal Health; Janssen; Karyopharm Therapeutics; Sanofi
Speakers' Bureau - Curio Science; MJH Life Sciences; NCCN; Targeted Oncology
Other Relationship - GlaxoSmithKline